Cognex Co. (NASDAQ:CGNX) Shares Sold by MetLife Investment Advisors LLC

MetLife Investment Advisors LLC trimmed its position in shares of Cognex Co. (NASDAQ:CGNX) by 0.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 104,987 shares of the scientific and technical instruments company’s stock after selling 328 shares during the period. MetLife Investment Advisors LLC owned approximately 0.06% of Cognex worth $4,060,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in CGNX. Oregon Public Employees Retirement Fund increased its holdings in Cognex by 3,621.7% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 3,422,295 shares of the scientific and technical instruments company’s stock valued at $89,000 after buying an additional 3,330,340 shares during the last quarter. Federated Investors Inc. PA grew its holdings in shares of Cognex by 2,019.9% during the third quarter. Federated Investors Inc. PA now owns 1,484,085 shares of the scientific and technical instruments company’s stock worth $82,842,000 after purchasing an additional 1,414,078 shares during the last quarter. Fundsmith LLP purchased a new position in shares of Cognex during the fourth quarter worth about $39,953,000. Sumitomo Mitsui Asset Management Company LTD grew its holdings in shares of Cognex by 5,315.2% during the fourth quarter. Sumitomo Mitsui Asset Management Company LTD now owns 880,401 shares of the scientific and technical instruments company’s stock worth $34,045,000 after purchasing an additional 864,143 shares during the last quarter. Finally, Eagle Asset Management Inc. grew its holdings in shares of Cognex by 12.0% during the fourth quarter. Eagle Asset Management Inc. now owns 3,679,715 shares of the scientific and technical instruments company’s stock worth $142,294,000 after purchasing an additional 395,461 shares during the last quarter. Institutional investors own 95.53% of the company’s stock.

Cognex stock traded down $0.26 during mid-day trading on Monday, reaching $54.57. The company had a trading volume of 623,276 shares, compared to its average volume of 1,225,232. Cognex Co. has a 1 year low of $34.88 and a 1 year high of $59.18. The stock has a market cap of $9.41 billion, a PE ratio of 44.01, a price-to-earnings-growth ratio of 2.88 and a beta of 1.99.

Cognex (NASDAQ:CGNX) last issued its earnings results on Thursday, February 14th. The scientific and technical instruments company reported $0.26 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.22 by $0.04. Cognex had a net margin of 27.19% and a return on equity of 19.75%. The company had revenue of $193.29 million during the quarter, compared to analysts’ expectations of $184.82 million. During the same period last year, the company posted ($0.16) earnings per share. The firm’s quarterly revenue was up 5.7% compared to the same quarter last year. On average, research analysts predict that Cognex Co. will post 1.26 earnings per share for the current fiscal year.

In other news, Director Theodor Krantz sold 30,000 shares of the firm’s stock in a transaction that occurred on Tuesday, February 26th. The shares were sold at an average price of $53.18, for a total transaction of $1,595,400.00. Following the completion of the transaction, the director now directly owns 52,500 shares of the company’s stock, valued at approximately $2,791,950. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 5.60% of the company’s stock.

Several brokerages have issued reports on CGNX. BidaskClub raised Cognex from a “hold” rating to a “buy” rating in a report on Thursday, February 14th. Zacks Investment Research upgraded shares of Cognex from a “hold” rating to a “buy” rating and set a $53.00 target price for the company in a research note on Monday, February 11th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $50.00 target price (up previously from $47.00) on shares of Cognex in a research note on Tuesday, February 12th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and six have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $48.71.

TRADEMARK VIOLATION WARNING: “Cognex Co. (NASDAQ:CGNX) Shares Sold by MetLife Investment Advisors LLC” was originally reported by Baseball Daily News and is owned by of Baseball Daily News. If you are viewing this piece of content on another publication, it was stolen and republished in violation of United States & international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.baseballdailydigest.com/news/2019/04/15/metlife-investment-advisors-llc-has-4-06-million-position-in-cognex-co-cgnx.html.

About Cognex

Cognex Corporation provides machine vision products that capture and analyze visual information in order to automate tasks primarily in manufacturing processes worldwide. It provides machine vision products, which are used to automate the manufacture and tracking of discrete items, including mobile phones, aspirin bottles, and automobile tires by locating, identifying, inspecting, and measuring them during the manufacturing or distribution process.

Featured Story: What is the price-sales ratio?

Institutional Ownership by Quarter for Cognex (NASDAQ:CGNX)

Receive News & Ratings for Cognex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cognex and related companies with MarketBeat.com's FREE daily email newsletter.